Grifols (GIKLY) EBITDA Margin Growth (1y) (2011 - 2020)
Grifols (GIKLY) EBITDA Margin Growth (1y) (2011 - 2020) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBITDA Margin Growth (1y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
660.00 |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-179.00 |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
-138.00 |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
-1,240.00 |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-6,345.00 |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
1,648.00 |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
360.00 |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
2,760.00 |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Grifols |
- |
- |
- |
- |
| Date | Value |
|---|
| Mar 31, 2020 |
-98.00 |
| Dec 31, 2019 |
6,358.00 |
| Mar 31, 2019 |
4,225.00 |
| Dec 31, 2018 |
-1,792.00 |
| Jun 30, 2018 |
-136.00 |
| Mar 31, 2018 |
-134.00 |
| Dec 31, 2017 |
-368.00 |
| Jun 30, 2017 |
363.00 |
| Mar 31, 2017 |
95.00 |
| Dec 31, 2016 |
-5,225.00 |
| Sep 30, 2016 |
-152.00 |
| Jun 30, 2016 |
-238.00 |
| Mar 31, 2016 |
-136.00 |
| Dec 31, 2015 |
4,904.00 |
| Sep 30, 2015 |
-39.00 |
| Jun 30, 2015 |
16.00 |
| Mar 31, 2015 |
277.00 |
| Dec 31, 2014 |
716.00 |
| Sep 30, 2014 |
-210.00 |
| Jun 30, 2014 |
-388.00 |
